Journal ArticleOPEN ACCESS

Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus

Kardiologiya (2022) 62(12) 64-72
DOI: 10.18087/cardio.2022.12.n1838
2Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Cite

CITATION STYLE

APA

Karetnikova, V. N., Horlampenko, A. A., Kochergina, A. M., Osokina, A. V., Gruzdeva, O. V., & Golubovskaya, D. P. (2022). Cardiometabolic Effects of Empagliflozin in Patients Undergoing Elective Percutaneous Coronary Intervention for Type 2 Diabetes Mellitus. Kardiologiya, 62(12), 64–72. https://doi.org/10.18087/cardio.2022.12.n1838

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free